
Obesity has emerged as a global epidemic and is a major risk factor for various chronic conditions, including insulin resistance, type 2 diabetes, and cardiovascular diseases. We aimed to investigate the validity of soluble suppression of tumorigenicity 2 (sST2), high sensitivity c-reactive protein (hs-CRP), malondialdehyde (MDA), and 8-hydroxy-2-deoxyguanosine (8-OHdG) as potential biomarkers for low-grade inflammation and oxidative stress in obese individuals. Moreover, to explore their association with metabolic dysfunctions. A recruited cohort of 90 subjects of both genders were categorized as obese (BMI BMI > 30 kg/m2). In addition to the glycemic and lipid profile, a panel of inflammatory (sST2 and hs-CRP) and oxidative stress biomarkers (DMA and 8-OHdG) were assessed using ELISA. Body Mass Index (BMI) and the mean diastolic blood pressure (DBP) were significantly higher in the obese subjects than in controls (p = 0.0001 and 0.03, respectively). Fasting blood sugar (FBS) and triglyceride (TG) were significantly higher in the study group (p = 0.01 and 0.001) compared to the control group. LDL showed substantial elevation in obese subjects (p = 0.001), but HDL was remarkably reduced (p = 0.02). The hs-CRP and sST2 levels were significantly elevated (p = 0.001) in obese individuals, and both MDA and 8-OHdG indicated a similar pattern (p = 0.001 and 0.000). BMI exhibited a positive correlation with all assessed inflammatory and oxidative stress biomarkers. In contrast, FBS and triglyceride (TG) demonstrated a significant association with hs-CRP, 8-OHdG, and MDA, but not with sST2. Furthermore, LDL, VLDL, and LDL/HDL showed a statistically significant positive correlation with hs-CRP and MDA. The elevated levels of all mediators were closely associated with metabolic dysfunction, emphasizing the interplay between obesity and low-grade chronic inflammation. This also highlights the potential for increased cardiovascular risk over time.
Citation: Kazheen Majeed, Hazhmat Ali. Association of low-grade inflammation and oxidative stress with metabolic dysfunction in healthy obese individuals[J]. AIMS Allergy and Immunology, 2025, 9(2): 56-69. doi: 10.3934/Allergy.2025004
[1] | Ibrahim Sambo Farouq, Nuraddeen Umar Sambo, Ali Umar Ahmad, Aminu Hassan Jakada, Isma'il Aliyu Danmaraya . Does financial globalization uncertainty affect CO2 emissions? Empirical evidence from some selected SSA countries. Quantitative Finance and Economics, 2021, 5(2): 247-263. doi: 10.3934/QFE.2021011 |
[2] | Iuliana Matei . Is financial development good for economic growth? Empirical insights from emerging European countries. Quantitative Finance and Economics, 2020, 4(4): 653-678. doi: 10.3934/QFE.2020030 |
[3] | Mustafa Hassan Mohammad Adam . Nexus among foreign direct investment, financial development, and sustainable economic growth: Empirical aspects from Sudan. Quantitative Finance and Economics, 2022, 6(4): 640-657. doi: 10.3934/QFE.2022028 |
[4] | Kuashuai Peng, Guofeng Yan . A survey on deep learning for financial risk prediction. Quantitative Finance and Economics, 2021, 5(4): 716-737. doi: 10.3934/QFE.2021032 |
[5] | Md Qamruzzaman, Jianguo Wei . Do financial inclusion, stock market development attract foreign capital flows in developing economy: a panel data investigation. Quantitative Finance and Economics, 2019, 3(1): 88-108. doi: 10.3934/QFE.2019.1.88 |
[6] | Mariam Naz, Syed Faizan Iftikhar, Ambreen Fatima . Does financial inclusiveness matter for the formal financial inflows? Evidence from Pakistan. Quantitative Finance and Economics, 2020, 4(1): 19-35. doi: 10.3934/QFE.2020002 |
[7] | Gigamon Joseph Prah . Innovation and economic performance: The role of financial development. Quantitative Finance and Economics, 2022, 6(4): 696-721. doi: 10.3934/QFE.2022031 |
[8] | Gaoke Liao, Zhenghui Li, Mengxin Wang, Khaldoon Albitar . Measuring China's urban digital finance. Quantitative Finance and Economics, 2022, 6(3): 385-404. doi: 10.3934/QFE.2022017 |
[9] | Naliniprava Tripathy . Does measure of financial development matter for economic growth in India?. Quantitative Finance and Economics, 2019, 3(3): 508-525. doi: 10.3934/QFE.2019.3.508 |
[10] | Tinghui Li, Jiehua Ma . Does digital finance benefit the income of rural residents? A case study on China. Quantitative Finance and Economics, 2021, 5(4): 664-688. doi: 10.3934/QFE.2021030 |
Obesity has emerged as a global epidemic and is a major risk factor for various chronic conditions, including insulin resistance, type 2 diabetes, and cardiovascular diseases. We aimed to investigate the validity of soluble suppression of tumorigenicity 2 (sST2), high sensitivity c-reactive protein (hs-CRP), malondialdehyde (MDA), and 8-hydroxy-2-deoxyguanosine (8-OHdG) as potential biomarkers for low-grade inflammation and oxidative stress in obese individuals. Moreover, to explore their association with metabolic dysfunctions. A recruited cohort of 90 subjects of both genders were categorized as obese (BMI BMI > 30 kg/m2). In addition to the glycemic and lipid profile, a panel of inflammatory (sST2 and hs-CRP) and oxidative stress biomarkers (DMA and 8-OHdG) were assessed using ELISA. Body Mass Index (BMI) and the mean diastolic blood pressure (DBP) were significantly higher in the obese subjects than in controls (p = 0.0001 and 0.03, respectively). Fasting blood sugar (FBS) and triglyceride (TG) were significantly higher in the study group (p = 0.01 and 0.001) compared to the control group. LDL showed substantial elevation in obese subjects (p = 0.001), but HDL was remarkably reduced (p = 0.02). The hs-CRP and sST2 levels were significantly elevated (p = 0.001) in obese individuals, and both MDA and 8-OHdG indicated a similar pattern (p = 0.001 and 0.000). BMI exhibited a positive correlation with all assessed inflammatory and oxidative stress biomarkers. In contrast, FBS and triglyceride (TG) demonstrated a significant association with hs-CRP, 8-OHdG, and MDA, but not with sST2. Furthermore, LDL, VLDL, and LDL/HDL showed a statistically significant positive correlation with hs-CRP and MDA. The elevated levels of all mediators were closely associated with metabolic dysfunction, emphasizing the interplay between obesity and low-grade chronic inflammation. This also highlights the potential for increased cardiovascular risk over time.
Colorectal cancer (CRC) is one of the leading causes of death associated with cancer worldwide, which has been estimated to cause 50,000 deaths per year in America [1,2]. The pathogenesis of CRC is a complicated process involved in mutations of various oncogenes and tumor suppressor genes that pinpoint multiple cellular events, such as endoplasmic reticulum stress [3], oxidative stress [4], epithelial-mesenchymal transition (EMT) [5], abnormal cell proliferation and apoptosis [6].
Although surgery combined with adjuvant radiotherapy or chemotherapy has effectively improved the prognosis of CRC, metastasis or neoplasm recurrence still occur in more than 50% of the CRC patients who have received a definite diagnosis or underwent intended curative treatment, contributing to a relatively poor 5-year survival rate [7]. Additionally, it is difficult for doctors to achieve early diagnosis of CRC for the reason that specificity of auxiliary examination indices is lacking in clinic, so that many patients may eventually miss the optional chances for surgery, thereby increasing the risk of death [8]. Hence, the detection of early-stage biomarkers and identification of core therapeutic target appear significant to decrease CRC-related deaths.
Recent years, the high-throughput gene microarray has been widely used to screen the differentially expressed genes (DEGs) between normal samples and tumor samples in human beings and animal models, which makes it accessible for us to further explore the entire molecular alterations of tumors at multiple levels involving DNA, RNA, proteins, epigenetic alterations, and metabolism [9,10]. However, it still has a long way to go to put these microarrays in application in clinic because the DEGs identified by gene profiling were countless and the statistical analyses were also too complicated [11]. Therefore, it is urgent to verify a proper number of genes and develop a suitable approach which can be operated by routine assay in clinic.
In this study, we selected the GSE32323 from Gene Expression Omnibus (GEO) and applied bioinformatics analysis to screen the DEGs in CRC. Subsequently, we used STRING to construct the protein-protein interaction (PPI) network to identify the hub genes with top15 degree of connectivity in CRC. Moreover, we made the analysis of these DEGs, including biological process (BP), molecular function (MF), cellular component (CC) and KEGG pathways. We chose top5 up-regulated and top5 down-regulated DEGs to make the overall survival (OS) analysis, aiming to observe the associations between the DEGs and the prognosis of CRC. Finally, we confirmed the mRNA expression level of the top5 up-regulated and top5 down-regulated DEGs by Q-PCR in samples obtained from patients with CRC in our hospital. These genes will assist us to screen and identify significant biomarkers and therapeutic targets of CRC in the near future.
The heading levels should not be more than 4 levels. The fond of heading and subheadings should be 12 point normal Times New Roman. The first letter of headings and subheadings should be capitalized. The gene expression profile of GSE32323 was downloaded from the GEO database, which was a free and publicly available database. 17 pairs of cancer and non-cancerous tissues from patients with CRC in this dataset were detected by Affymetrix HG-U133 Plus 2.0 arrays by Ahmed K [12]. We also downloaded the raw Series Matrix File of GSE32323 from the GEO database.
In our study, the online software GEO2R was employed to analyze the tissue samples in GSE32323 dataset. GEO2R is an online software by which users can divide the samples into two and more groups and select out the DEGs. We used the Benjamini and Hochberg methods by default to discover false rate and used the adjust P value to reduce the errors of false positive. The choice criterion contains the adjust P value < 0.05 and |logFC| ≥ 2.
Gene ontology analysis (GO), serving as a useful approach to annotate genes and gene products, could also identify characteristic biological attributing to high-throughput genome or transcriptome data. Kyoto Encyclopedia of Genes and Genomes (KEGG) is a collection of databases, aiming to handle biological pathways, genomes, diseases, chemical substances and drugs. We divided these DEGs into up-regulated group and down-regulated group. The Database for Annotation, Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/), an online web based on the bioinformatics, is routinely applied for annotating genes and protein function [13]. We input these DEGs separately into DAVID to acquire the GO and KEGG analysis, P < 0.05 as choice criterion. Finally, we used the ImageGP (http://www.ehbio.com/ImageGP/index.php/Home/Index/index.html) to visualize the major biological processes (BP), molecular function (MF) and cell composition (CC) of these DEGs.
GEPIA (http://gepia.cancer-pku.cn/index.html), designed by Chenwei Li, Zefang Tang, and Boxi Kang of Zhang Lab, Peking University, is a newly developed interactive web server aiming at analyzing the RNA sequencing expression data of 9736 tumors and 8587 normal samples from the GTEx and TCGA projects in a standard processing pipeline [14]. In this study, we employed the boxplot to visualize the mRNA expression of top5 up-regulated and top5 down-regulated DEGs in CRC tissues and and normal colorectum tissues. Transcripts per million (TPM) is the number of transcripts from this particular gene normalized first by gene length, and then by sequencing depth (in millions) in the sample. GEPIA also provides the transcripts per million (TPM) of these DEGs to display their relative expression levels.
Similarly, we used the GEPIA database to get the overall survival information of these DEGs. The logrank P value and hazard ratio (HR) with 95% confidence intervals were showed on the plot. P < 0 05 was statistically significant.
We enrolled 15 male patients who were diagnosed with CRC by pathology reports in our hospital. The samples from patients with CRC for the validation of these DEGs were supported by the ethics committee in our hospital. The paired carcinoma and adjacent tissues were firstly isolated. Then total RNA was isolated using the TRIzol (Invitrogen, Carlsbad, CA, USA) kit, the concentrations and purities of which were quantified by an ultraviolet spectrophotometer. The RNA was then reversely transcribed according to the previous literature [15]. The expression levels of top5 up-regulated genes and top5 down-regulated genes were normalized to GAPDH. Relative mRNA expression levels were analyzed by 2-∆∆cycle threshold (CT) method.
Search Tool for the Retrieval of Interacting Genes (STRING) is an online app for evaluating PPI network [16]. For finding the potential correlation of DEGs, we used online app STRING to map the DEGs, subsequently the Cytoscape software was utilized to construct a PPI network. The confidence score ≥ 0.4 and maximum number of interactors = 0 were set as the criterion.
The overall flow diagram of our study is presented in Figure 1. In our study, a total of 17 paired carcinoma and adjacent tissue from patients with CRC were analyzed. We applied the GEO2R online analysis tool with default parameters to screen the DEGs, using adjusted P value < 0.05 and logFC ≤ −2 or logFC ≥ 2 as the cut-off criteria. We captured 451 DEGs including 145 up-regulated DEGs and 306 downregulated DEGs. Whereafter, the DEGs were presented in the form of a heatmap and a volcano plot (Figure 2A-B). In the heatmap, the top25 up-regulated genes and top25 down-regulated genes between carcinoma and adjacent tissue were presented. Among the 451 DEGs, the top5 up-regulated genes involved DPEP1, KRT23, CLDN1, LGR5 and FOXQ1, while the top5 down-regulated genes were CLCA4, ZG16, SLC4A4, ADH1B and GCG. The gene tiles and biological functions of top5 upregulated and top5 down regulated genes were displayed in Table 1.
DEGs | Gene title | Gene symbol | LogFC | Biological function |
Down-regulated | Chloride channel accessory 4 | CLCA4 | 4.91 | Calcium sensitive chloride conductance protein |
Zymogen granule protein 16 | ZG16 | 4.45 | Promoting cell growth and stemness. | |
Solute carrier family 4 member 4 | SLC4A4 | 4.43 | Sodium bicarbonate cotransporter | |
Alcohol dehydrogenase 1B (class I), beta polypeptide | ADH1B | 4.29 | Metabolizing ethanol, retinol, and aliphatic alcohol | |
Glucagon | GCG | 4.15 | Counteracting the action of insulin in the bloodstream. | |
Up-regulated | Dipeptidase 1 | DPEP1 | −4.14 | Kidney membrane enzyme |
Keratin 23 | KRT23 | −4.28 | Intermediate filament proteins | |
Claudin 1 | CLDN1 | −4.46 | Tight junctions | |
Leucine rich repeat containing G protein-coupled receptor 5 | LGR5 | −4.51 | Leucine-rich repeat-containing receptor | |
Forkhead box Q1 | FOXQ1 | −5.55 | Embryonic development and cell cycle regulation |
To ensure the credibility and reliability of the microarray of GSE32323 and get further credible analysis, we re-identified the top5 up-regulated genes and top5 down-regulated genes via Q-PCR. Q-PCR (Figure 5A-B) showed that the mRNA expression levels of DPEP1, KRT23, CLDN1, LGR5 and FOXQ1 were significantly higher in carcinoma group compared with adjacent tissue group (P < 0.05). Meantime, the mRNA expression levels of CLCA4, ZG16, SLC4A4, ADH1B and GCG were obviously down-regulated in carcinoma tissues from patients with CRC (P < 0.05).
To ensure the credibility of the microarray of GSE32323 and proceed further credible analysis, we validated the top5 up-regulated genes and top5 down-regulated genes based on TCGA database via GEPIA. The results showed that the mRNA expression levels of CLCA4, ZG16, SLC4A4, ADH1B and GCG were significantly lower in carcinoma group compared to adjacent tissue group while the mRNA expression level of DPEP1, KRT23, CLDN1, LGR5 and FOXQ1 in carcinoma group were statistically higher than the adjacent tissue group (P < 0.05) (Figure 3A-J). Meanwhile, the TPM analysis demonstrated that the relative expressions of these DEGs were consist with those based on GSE32323 (P < 0.05) (Figure 4A-J).
Furthermore, we analyzed the potential association between the expression levels of top5 upregulated genes as well as top5 downregulated genes and the OS of patients with CRC. The Kaplan-Meier showed that only 1(ZG16) of the 10 genes displayed significantly correlation with the OS of patients with CRC (Figure 6A-J). The high level of ZG16 may contribute to a poorer prognosis of CRC (Logrank p = 0.044, HR = 0.61).
The results (Table2 & Figure 7A-C) from GO term enrichment analysis varied from expression levels and GO classification of the DEGs. By analyzing GO enrichment of these up-regulated and down-regulated DEGs via DAVID, we found that the up-regulated DEGs in BP were mainly enriched in negative regulation of cell proliferation, positive regulation of transcription from RNA polymerase Ⅱ promoter, proteolysis, positive regulation of transcription, DNA-templated and negative regulation of transcription from RNA polymerase Ⅱ promoter while the down-regulated DEGs in BP were mainly concentrated on cell adhesion, negative regulation of cell proliferation, positive regulation of cell proliferation, response to drug and nervous system development. As for CC, the up-regulated DEGs were principally enriched in extracellular region, extracellular space, integral component of plasma membrane, proteinaceous extracellular matrix and cell surface while the down-regulated DEGs were enriched in integral component of membrane, plasma membrane, extracellular exosome, extracellular space and extracellular region. Additionally, MF analysis uncovered that the up-regulated DEGs were mainly enriched in chemokine activity, CXCR chemokine receptor binding, serine-type endopeptidase activity, extracellular matrix binding and Wnt-protein binding while the down-regulated DEGs are responsible for carbonate dehydratase activity, heparin binding, structural constituent of cytoskeleton, hormone activity and zinc ion binding.
Expression | Category | Term | Count | % | P-Value | FDR |
Down-regulated | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 13 | 0.038728513 | 0.013503078 | 19.70156803 |
GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.035749397 | 0.011658571 | 17.24378143 | |
GOTERM_BP_DIRECT | GO:0008284~positive regulation of cell proliferation | 11 | 0.03277028 | 0.07067658 | 69.36458376 | |
GOTERM_BP_DIRECT | GO:0042493~response to drug | 10 | 0.029791164 | 0.014890967 | 21.50558949 | |
GOTERM_BP_DIRECT | GO:0007399~nervous system development | 9 | 0.026812048 | 0.028891454 | 37.69742039 | |
GOTERM_CC_DIRECT | GO:0016021~integral component of membrane | 83 | 0.247266661 | 0.004198766 | 5.157367461 | |
GOTERM_CC_DIRECT | GO:0005886~plasma membrane | 71 | 0.211517264 | 0.001689338 | 2.105290204 | |
GOTERM_CC_DIRECT | GO:0070062~extracellular exosome | 67 | 0.199600798 | 6.59E-08 | 8.30E-05 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 43 | 0.128102005 | 1.82E-08 | 2.29E-05 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 34 | 0.101289957 | 0.002466544 | 3.060090837 | |
GOTERM_MF_DIRECT | GO:0004089~carbonate dehydratase activity | 5 | 0.014895582 | 1.89E-05 | 0.0259938 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 9 | 0.026812048 | 7.38E-04 | 1.012297275 | |
GOTERM_MF_DIRECT | GO:0005200~structural constituent of cytoskeleton | 7 | 0.020853815 | 0.002187539 | 2.974720065 | |
GOTERM_MF_DIRECT | GO:0005179~hormone activity | 6 | 0.017874698 | 0.005649705 | 7.515474579 | |
GOTERM_MF_DIRECT | GO:0008270~zinc ion binding | 25 | 0.07447791 | 0.007595654 | 9.980321245 | |
Up-regulated | GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.072115385 | 4.45E-05 | 0.070505424 |
GOTERM_BP_DIRECT | GO:0045944~positive regulation of transcription from RNA polymerase Ⅱ promoter | 12 | 0.072115385 | 0.047923342 | 54.04862787 | |
GOTERM_BP_DIRECT | GO:0006508~proteolysis | 10 | 0.060096154 | 0.004653246 | 7.118885476 | |
GOTERM_BP_DIRECT | GO:0045893~positive regulation of transcription, DNA-templated | 10 | 0.060096154 | 0.005625306 | 8.544770506 | |
GOTERM_BP_DIRECT | GO:0000122~negative regulation of transcription from RNA polymerase Ⅱ promoter | 10 | 0.060096154 | 0.040288919 | 47.85424336 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 25 | 0.150240385 | 2.24E-05 | 0.026796109 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 23 | 0.138221154 | 1.30E-05 | 0.015593466 | |
GOTERM_CC_DIRECT | GO:0005887~integral component of plasma membrane | 17 | 0.102163462 | 0.0098955 | 11.22182273 | |
GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 10 | 0.060096154 | 3.33E-05 | 0.039831238 | |
GOTERM_CC_DIRECT | GO:0009986~cell surface | 8 | 0.048076923 | 0.044084961 | 41.70407607 | |
GOTERM_MF_DIRECT | GO:0008009~chemokine activity | 6 | 0.036057692 | 1.24E-05 | 0.016078978 | |
GOTERM_MF_DIRECT | GO:0045236~CXCR chemokine receptor binding | 4 | 0.024038462 | 1.86E-05 | 0.024112254 | |
GOTERM_MF_DIRECT | GO:0004252~serine-type endopeptidase activity | 8 | 0.048076923 | 0.00101144 | 1.305200327 | |
GOTERM_MF_DIRECT | GO:0050840~extracellular matrix binding | 3 | 0.018028846 | 0.01109514 | 13.48485303 | |
GOTERM_MF_DIRECT | GO:0017147~Wnt-protein binding | 3 | 0.018028846 | 0.01556121 | 18.42243874 | |
GO: Gene Ontology; FDR: False Discovery Rate. |
To obtain a more comprehensive information regarding to the critical pathways of those selected DEGs, KEGG pathways analysis were also carried out via DAVID. The results in Table3 and Figure 7D disclosed the most vital KEGG pathways of the down-regulated and up-regulated DEGs. The down-regulated DEGs were mainly enriched in mineral absorption, pancreatic secretion, nitrogen metabolism, aldosterone-regulated sodium reabsorption and bile secretion. By contrast, the up-regulated DEGs were mainly responsible for chemokine signaling pathway, pathways in cancer, transcriptional misregulation in cancer, PPAR signaling pathway and rheumatoid arthritis.
Category | Term | Count | % | P-Value | Genes | FDR |
Down-regulatedDEGs | hsa04978:Mineral absorption | 6 | 0.017874698 | 4.69E-04 | TRPM6, MT1M, MT1E, MT1H, MT1X, MT1F | 0.546769342 |
hsa04972:Pancreatic secretion | 6 | 0.017874698 | 0.010495925 | KCNMA1, CLCA1, CLCA4, ATP2A3, CA2, SLC4A4 | 11.59221263 | |
hsa00910:Nitrogen metabolism | 5 | 0.014895582 | 8.18E-05 | CA12, CA7, CA4, CA2, CA1 | 0.095443878 | |
hsa04960:Aldosterone-regulated sodium reabsorption | 5 | 0.014895582 | 0.002219912 | SGK1, NR3C2, HSD11B2, SCNN1G, SCNN1B | 2.561720438 | |
hsa04976:Bile secretion | 5 | 0.014895582 | 0.016846119 | AQP8, SLC51B, CA2, SLC4A4, ABCG2 | 17.99502607 | |
Up-regulatedDEGs | hsa04062:Chemokine signaling pathway | 7 | 0.042067308 | 0.001681492 | CXCL1, PLCB4, PPBP, CXCL5, CXCL3, CXCL8, CXCL11 | 1.951113014 |
hsa05200:Pathways in cancer | 7 | 0.042067308 | 0.053070195 | BMP4, PLCB4, MET, CXCL8, AXIN2, MYC, MMP1 | 47.1893587 | |
hsa05202:Transcriptional misregulation in cancer | 6 | 0.036057692 | 0.005889645 | MET, CXCL8, MMP3, MYC, WT1, PLAU | 6.682415976 | |
hsa03320:PPAR signaling pathway | 4 | 0.024038462 | 0.011041824 | SCD, ACSL6, MMP1, FABP6 | 12.19046418 | |
hsa05323:Rheumatoid arthritis | 4 | 0.024038462 | 0.022861328 | CXCL5, CXCL8, MMP3, MMP1 | 23.72114711 | |
KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: False Discovery Rat |
Applying the STRING online tool, 213 nodes with 264 PPI relationships were found, accounting for about 77.8% of these selected DEGs. According to the degree of connectivity of these DEGs, we constructed the PPI network and selected the top 15 hub genes (Table 4). The top 15 hub genes, possessing high degree of connectivity in CRC are as follows, MYC, CXCR1, TOP2A, CXCL12, SST, TIMP1, SPP1, PPBP, CDK1, THBS1, CXCL1, PYY, LPAR1, BMP2 and MMP3. Among these 15 hub genes: MYC, CXCR1, TOP2A, SPP1, PPBP, CDK1, CXCL1 and MMP3 were significantly up-regulated while CXCL12, SST, TIMP1, THBS1, PYY, LPAR1 and BMP2 significantly down-regulated (P < 0.05). The 15 hub genes could interact with 243 genes directly, and MYC acted as the most intensive gene which could interact with 46 up-regulated genes and 31 down-regulated genes. Intriguingly, among these hub genes, there also displayed very strong interactions (Figure 8).
Gene | Degree of connectivity | Adjusted P value |
MYC | 34 | 9.25E-11 |
CXCR1 | 28 | 1.87E-03 |
TOP2A | 23 | 2.90E-02 |
CXCL12 | 20 | 1.95E-08 |
SST | 18 | 7.36E-09 |
TIMP1 | 17 | 1.05E-02 |
SPP1 | 17 | 3.95E-02 |
PPBP | 17 | 9.73E-04 |
CDK1 | 16 | 1.13E-02 |
THBS1 | 16 | 2.99E-08 |
CXCL1 | 15 | 1.91E-03 |
PYY | 15 | 1.77E-08 |
LPAR1 | 15 | 8.36E-11 |
BMP2 | 15 | 1.06E-05 |
MMP3 | 14 | 7.22E-05 |
CRC is a one of the serious public health problems, which is also being the third most commonly diagnosed cancer and the major factor resulting in cancer-related deaths around the world [17,18]. CRC screening has been demonstrated to greatly decrease the morbidity and the mortality in a great many longstanding or newly economically developed countries [19]. However, at present, there is no an efficient and specific diagnostic methodology and treatment strategy for CRC, which is mainly attributed to the intricate pathogenesis, and its symptoms that are difficult to diagnose in the first several years [20]. Our study mainly focused on the expression profiling selected from microarray studies of CRC. In this study, a total of 17 pairs of cancer and non-cancerous tissues isolated from patients with CRC were analyzed. 451 DEGs including 145 up-regulated DEGs and 306 downregulated DEGs were screened. To obtain a comprehensive understanding of these DEGs, we performed GO function and KEGG pathway analysis.
Our analysis screened 451 DEGs with a quadruple fold change between carcinoma and adjacent tissue from patients with CRC. In our heat map, a total of 50 DEGs including top25 up-regulated genes and top25 down-regulated genes were displayed. From our perspective, these DEGs would be promised to be possible candidates for the diagnosis of CRC in future. Currently, some of these DEGs, in fact, have been already disclosed to be novel indicators of CRC. H Meng et al. [21] found that ZG16 exhibited an extremely high expression in normal epithelial cells from rectum, colon and small intestine in an organ-specific fashion while its protein expression was completely lost in CRC tissues. Furthermore, another study proved that the gene expression and copy number alterations of ZG16 significantly correlated with MLH1 silencing, microsatellite instability (MSI), hyper-mutation status, presence of synchronous adenomas, CpG island methylator phenotype, histological type and gender. Survival analysis showed that patients with higher ZG16 gene expression level displayed longer overall survival and progression-free survival compared with those having relatively lower level. Another study showed that the expression of DPEP1 was strikingly up-regulated in human CRC tissue than that in normal mucosa. Meanwhile, high level of DPEP1 was found to be significantly associated with localisation and histological stage of CRC [22]. Our study screened the DEGs of CRC from the angle of bioinformatics for the first time, however, the clinical practice of these DEGs needs to be further investigated.
In our study, we picked out 15 hub genes of CRC, all of which were located in the core nodes in PPI network, meaning that these genes could be critical therapeutic targets to protect against CRC. For instance, somatostatin (SST), encoding a well-characterized growth-regulatoryand gastrointestinal neuroendocrine peptide, has been proved to be a tumor suppressor gene and own potent anti-tumor effects. SST could suppress tumors through direct and indirect mechanisms. Direct anti-tumor effects involve inhibiting cell proliferation; inducing cell cycle arrest; promoting apoptosis; and suppressing cell invasion while indirect anti-tumor effects are blocking the synthesis and secretion of growth factors as well as growth-promoting hormones, meanwhile stopping angiogenesis which is vital in neoplasm growth and spread [23]. Corroborative evidence has unveiled the decreased protein and mRNA expression of SST in CRC tissues [24]. One of the possible reason contributing to the down-regulation of SST was attributed to the higher SST methylation levels in tumor tissues. As expected, another study showed that pretreatment of demethylation agents into SST methylated CRC cells induced the up-regulation of SST expression in vitro [25]. Clinical research demonstrated that serum methylation level of SST in patients with CRC were obviously predictive of tumor recurrence and cancer-related death [26]. Collectively, our study proved that up-regulating SST in CRC cells may exert potent anti-tumor activity.
An interesting finding of our study was that many DEGs in CRC were related with chemokines and their receptors. To be more specific, GO analysis showed that up-regulated DEGs enriched in MF were mainly responsible for chemokine activity and CXCR chemokine receptor binding. Also, KEGG pathways analysis also disclosed that the up-regulated genes including CXCL1, PLCB4, PPBP, CXCL5, CXCL3, CXCL8, CXCL11 are implicated with chemokine signaling pathway. Additionally, 3 of the top15 hub genes based PPI network were also chemokines and their receptors, namely CXCR1, CXCL12 and CXCL1. Mountainous evidence proved that the interactions between chemokines as well as chemokine receptors could mediate the recruitment of different immune cell subsets into tumour microenvironment where the host immune system and tumour cells could interact [27]. On the one hand, chemokines regulate the molecules affecting tumour immunity as well as therapeutic outcomes in patients [28,29]. On the other one hand, chemokines could also target stromal cells and tumor cells, thereby regulating tumour stemness, angiogenesis [30], proliferation [31], apoptosis [32], and survival [33]. These findings suggested that therapies targeting chemokines in CRC may synergize with current cancer therapies, especially immunotherapies by affecting tumour immunological phenotypes, and improving antitumour immune responses.
In conclusion, we provided a comprehensive and novel analysis of gene expression profiles patients with CRC. Particularly, the top5 down-regulated genes including CLCA4, ZG16, SLC4A4, ADH1B and GCG and the top5 up-regulated genes including DPEP1, KRT23, CLDN1, LGR5 and FOXQ1, which are expected to sensitive biomarkers in diagnosis of CRC. Meanwhile, we also screened the top 15 hub genes involving MYC, CXCR1, TOP2A, CXCL12, SST, TIMP1, SPP1, PPBP, CDK1, THBS1, CXCL1, PYY, LPAR1, BMP2 and MMP3, which could be promising therapeutic targets of CRC. Additionally, genes involved in chemokines pathways were also significantly altered in patients with CRC. Anyway, this analysis may offer the powerful evidence and clues for the future genomic individualized treatment of CRC.
This work was supported by the Science and Technology Project of Zhejiang Province (2014C33147), High-level Talent Project of Lishui City (2016RC29), Zhejiang Province Medical and Health Care Project (2017KY728) and National Natural Science Foundation of China (81803778).
All authors declare no conflicts of interest in this paper.
[1] |
Chew NWS, Ng CH, Tan DJH, et al. (2023) The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab 35: 414-428.e3. https://doi.org/10.1016/j.cmet.2023.02.003 ![]() |
[2] |
Mayoral LP, Andrade GM, Mayoral EP, et al. (2020) Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res 151: 11-21. https://doi.org/10.4103/ijmr.IJMR_1768_17 ![]() |
[3] |
Blüher M (2019) Obesity: Global epidemiology and pathogenesis. Nat Rev Endocrinol 15: 288-298. https://doi.org/10.1038/s41574-019-0176-8 ![]() |
[4] |
Swinburn BA, Sacks G, Hall KD, et al. (2011) The global obesity pandemic: Shaped by global drivers and local environments. Lancet 378: 804-814. https://doi.org/10.1016/S0140-6736(11)60813-1 ![]() |
[5] |
Kulkarni K, Karssiens T, Kumar V, et al. (2016) Obesity and osteoarthritis. Maturitas 89: 22-28. https://doi.org/10.1016/j.maturitas.2016.04.006 ![]() |
[6] |
Arroyo-Johnson C, Mincey KD (2016) Obesity epidemiology worldwide. Gastroenterol Clin North Am 45: 571-579. https://doi.org/10.1016/j.gtc.2016.07.012 ![]() |
[7] |
Wright SM, Aronne LJ (2012) Causes of obesity. Abdom Imaging 37: 730-732. https://doi.org/10.1007/s00261-012-9862-x ![]() |
[8] |
Bray GA, Kim KK, Wilding JPH (2017) Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 18: 715-723. https://doi.org/10.1111/obr.12551 ![]() |
[9] | Khanna D, Khanna S, Khanna P, et al. (2022) Obesity: A chronic low-grade inflammation and its markers. Cureus 14: e22711. https://doi.org/10.7759/cureus.22711 |
[10] |
Furman D, Campisi J, Verdin E, et al. (2019) Chronic inflammation in the etiology of disease across the life span. Nat Med 25: 1822-1832. https://doi.org/10.1038/s41591-019-0675-0 ![]() |
[11] |
Hajam YA, Rani R, Ganie SY, et al. (2022) Oxidative stress in human pathology and aging: Molecular mechanisms and perspectives. Cells 11: 552. https://doi.org/10.3390/cells11030552 ![]() |
[12] |
Čolak E, Pap D (2021) The role of oxidative stress in the development of obesity and obesity-related metabolic disorders. J Med Biochem 40: 1-9. https://doi.org/10.5937/jomb0-24652 ![]() |
[13] |
Engin A (2024) Endothelial dysfunction in obesity and therapeutic targets. Adv Exp Med Biol 1460: 489-538. https://doi.org/10.1007/978-3-031-63657-8_17 ![]() |
[14] |
Chao AM, Quigley KM, Wadden TA (2021) Dietary interventions for obesity: Clinical and mechanistic findings. J Clin Invest 131: e140065. https://doi.org/10.1172/JCI140065 ![]() |
[15] |
Celik O, Yildiz BO (2021) Obesity and physical exercise. Minerva Endocrinol 46: 131-144. https://doi.org/10.23736/S2724-6507.20.03361-1 ![]() |
[16] |
Kristensen SL, Rørth R, Jhund PS, et al. (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7: 776-785. https://doi.org/10.1016/S2213-8587(19)30249-9 ![]() |
[17] |
Kawai T, Autieri MV, Scalia R (2021) Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 320: C375-C391. https://doi.org/10.1152/ajpcell.00379.2020 ![]() |
[18] | Lim Y, Boster J (2024) Obesity and Comorbid Conditions. Florida: StatPearls Publishing. Available from: https://pubmed.ncbi.nlm.nih.gov/34662049/ |
[19] | Whelton PK, Carey RM, Aronow WS, et al. (2018) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 71: e136-e139. https://doi.org/10.1161/HYP.0000000000000080 |
[20] | World Health OrganizationMean fasting blood glucose (2025). Available from: https://www.who.int/data/gho/indicator-metadata-registry/imr-details/2380 |
[21] |
Martin SS, Blaha MJ, Elshazly MB, et al. (2013) Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 310: 2061-2068. https://doi.org/10.1001/jama.2013.280532 ![]() |
[22] |
Roberto CA, Swinburn B, Hawkes C, et al. (2015) Patchy progress on obesity prevention: Emerging examples, entrenched barriers, and new thinking. Lancet 385: 2400-2409. https://doi.org/10.1016/S0140-6736(14)61744-X ![]() |
[23] | Frigolet ME, Gutiérrez-Aguilar R (2020) The colors of adipose tissue. Gac Med Mex 156: 142-149. https://doi.org/10.24875/GMM.M20000356 |
[24] |
Stanhope KL (2016) Sugar consumption, metabolic disease and obesity: The state of the controversy. Crit Rev Clin Lab Sci 53: 52-67. https://doi.org/10.3109/10408363.2015.1084990 ![]() |
[25] |
Shabana, Shahid SU, Sarwar S (2020) The abnormal lipid profile in obesity and coronary heart disease (CHD) in Pakistani subjects. Lipids Health Dis 19: 73. https://doi.org/10.1186/s12944-020-01248-0 ![]() |
[26] |
Nejat A, Mirbolouk M, Mohebi R, et al. (2014) Changes in lipid measures and incident coronary heart disease: Tehran lipid & glucose study. Clin Biochem 47: 1239-1244. https://doi.org/10.1016/j.clinbiochem.2014.03.004 ![]() |
[27] | Szczygielska A, Widomska S, Jaraszkiewicz M, et al. (2003) Blood lipids profile in obese or overweight patients. Ann Univ Mariae Curie Sklodowska Med 58: 343-349. |
[28] |
Ahmed B, Sultana R, Greene MW (2021) Adipose tissue and insulin resistance in obese. Biomed Pharmacother 137: 111315. https://doi.org/10.1016/j.biopha.2021.111315 ![]() |
[29] |
Sudhakar M, Silambanan S, Chandran AS, et al. (2018) C-Reactive Protein (CRP) and leptin receptor in obesity: Binding of monomeric CRP to leptin receptor. Front Immunol 9: 1167. https://doi.org/10.3389/fimmu.2018.01167 ![]() |
[30] | Han H, Cho YH, Lee SY, et al. (2019) Elevated C-reactive protein level, obesity, and quality of life. J Pak Med Assoc 69: 1771-1776. https://doi.org/10.5455/JPMA.298182 |
[31] |
Kemalasari I, Fitri NA, Sinto R, et al. (2022) Effect of calorie restriction diet on levels of C reactive protein (CRP) in obesity: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr 16: 102388. https://doi.org/10.1016/j.dsx.2022.102388 ![]() |
[32] |
Krychtiuk KA, Stojkovic S, Lenz M, et al. (2018) Predictive value of low interleukin-33 in critically ill patients. Cytokine 103: 109-113. https://doi.org/10.1016/j.cyto.2017.09.017 ![]() |
[33] |
Homsak E, Gruson D (2020) Soluble ST2: A complex and diverse role in several diseases. Clin Chim Acta 507: 75-87. https://doi.org/10.1016/j.cca.2020.04.011 ![]() |
[34] |
Zeyda M, Wernly B, Demyanets S, et al. (2013) Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes 37: 658-665. https://doi.org/10.1038/ijo.2012.118 ![]() |
[35] |
Cayrol C, Girard JP (2018) Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev 281: 154-168. https://doi.org/10.1111/imr.12619 ![]() |
[36] |
Demyanets S, Kaun C, Kaider A, et al. (2020) The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery. Cardiovasc Diabetol 19: 26. https://doi.org/10.1186/s12933-020-01001-y ![]() |
[37] |
Ahima RS, Lazar MA (2008) Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol 22: 1023-1031. https://doi.org/10.1210/me.2007-0529 ![]() |
[38] |
Hotamisligil GS (2017) Inflammation, metaflammation and immunometabolic disorders. Nature 542: 177-185. https://doi.org/10.1038/nature21363 ![]() |
[39] |
Pérez-Torres I, Castrejón-Téllez V, Soto ME, et al. (2021) Oxidative Stress, plant natural antioxidants, and obesity. Int J Mol Sci 22: 1786. https://doi.org/10.3390/ijms22041786 ![]() |
[40] |
Rudich A, Tirosh A, Potashnik R, et al. (1998) Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 47: 1562-1569. https://doi.org/10.2337/diabetes.47.10.1562 ![]() |
[41] |
Ren J, Li Y, Wu Q, et al. (2023) Oxidative stress: The nexus of obesity and cognitive dysfunction in diabetes. Front Endocrinol 14: 1134025. https://doi.org/10.3389/fendo.2023.1134025 ![]() |
[42] |
Huang Y, Chen H, Liu Q, et al. (2023) Obesity difference on association blood malondialdehyde level and diastolic hypertension in the elderly population: A cross-sectional analysis. Eur J Med Res 28: 44. https://doi.org/10.1186/s40001-022-00983-7 ![]() |
[43] |
Prázný M, Skrha J, Hilgertová J (1999) Plasma malondialdehyde and obesity: Is there a relationship?. Clin Chem Lab Med 37: 1129-1130. https://doi.org/10.1515/CCLM.1999.164 ![]() |
[44] | Valavanidis A, Vlachogianni T, Fiotakis C (2009) 8-hydroxy-2′-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27: 120-139. https://doi.org/10.1080/10590500902885684 |
[45] |
Di Minno A, Turnu L, Porro B, et al. (2016) 8-Hydroxy-2-Deoxyguanosine Levels and Cardiovascular Disease: A systematic review and meta-analysis of the literature. Antioxid Redox Signal 24: 548-555. https://doi.org/10.1089/ars.2015.6508 ![]() |
[46] |
Sova H, Puistola U, Morin-Papunen L, et al. (2013) Metformin decreases serum 8-hydroxy-2′-deoxyguanosine levels in polycystic ovary syndrome. Fertil Steril 99: 593-598. https://doi.org/10.1016/j.fertnstert.2012.10.013 ![]() |
[47] |
García-Sánchez A, Gómez-Hermosillo L, Casillas-Moreno J, et al. (2023) Prevalence of hypertension and obesity: Profile of mitochondrial function and markers of inflammation and oxidative stress. Antioxidants 12: 165. https://doi.org/10.3390/antiox12010165 ![]() |
1. | Min Hong, Benjamin Drakeford, Kexian Zhang, The impact of mandatory CSR disclosure on green innovation: evidence from China, 2020, 2, 2643-1092, 302, 10.3934/GF.2020017 | |
2. | Cenjie Liu, Zhongbao Zhou, Qing Liu, Rui Xie, Ximei Zeng, Can a low-carbon development path achieve win-win development: evidence from China’s low-carbon pilot policy, 2020, 25, 1381-2386, 1199, 10.1007/s11027-019-09897-y | |
3. | Zimei Huang, Tinghui Li, Mark Xu, Are There Heterogeneous Impacts of National Income on Mental Health?, 2020, 17, 1660-4601, 7530, 10.3390/ijerph17207530 | |
4. | Zhenghui Li, Gaoke Liao, Khaldoon Albitar, Does corporate environmental responsibility engagement affect firm value? The mediating role of corporate innovation, 2020, 29, 0964-4733, 1045, 10.1002/bse.2416 | |
5. | Tinghui Li, Gaoke Liao, The Heterogeneous Impact of Financial Development on Green Total Factor Productivity, 2020, 8, 2296-598X, 10.3389/fenrg.2020.00029 | |
6. | Paul Adjei Kwakwa, Hamdiyah Alhassan, George Adu, Effect of natural resources extraction on energy consumption and carbon dioxide emission in Ghana, 2020, 14, 1750-6220, 20, 10.1108/IJESM-09-2018-0003 | |
7. | Yuhang Zheng, Shuanglian Chen, Nan Wang, Does financial agglomeration enhance regional green economy development? Evidence from China, 2020, 2, 2643-1092, 173, 10.3934/GF.2020010 | |
8. | Paul Adjei Kwakwa, Frank Adusah-Poku, The carbon dioxide emission effects of domestic credit and manufacturing indicators in South Africa, 2020, 31, 1477-7835, 1531, 10.1108/MEQ-11-2019-0245 | |
9. | Siming Liu, Peng Hou, Yingkun Gao, Yong Tan, Innovation and green total factor productivity in China: a linear and nonlinear investigation, 2020, 0944-1344, 10.1007/s11356-020-11436-1 | |
10. | Peirong Chen, Ruhe Xie, Mingxuan Lu, Zuqing Huang, The impact of the spatio-temporal neighborhood effect on urban eco-efficiency in China, 2021, 285, 09596526, 124860, 10.1016/j.jclepro.2020.124860 | |
11. | Hamdiyah Alhassan, Paul Adjei Kwakwa, Ebenezer Owusu-Sekyere, Households' source separation behaviour and solid waste disposal options in Ghana's Millennium City, 2020, 259, 03014797, 110055, 10.1016/j.jenvman.2019.110055 | |
12. | Zhenghui Li, Hao Dong, Zimei Huang, Pierre Failler, Impact of Foreign Direct Investment on Environmental Performance, 2019, 11, 2071-1050, 3538, 10.3390/su11133538 | |
13. | Yue Liu, Siming Liu, Xueying Xu, Pierre Failler, Does Energy Price Induce China’s Green Energy Innovation?, 2020, 13, 1996-1073, 4034, 10.3390/en13154034 | |
14. | Helian Xu, Guomei Zhao, Rui Xie, Kunfu Zhu, A trade-related CO2 emissions and its composition: Evidence from China, 2020, 270, 03014797, 110893, 10.1016/j.jenvman.2020.110893 | |
15. | Paul Adjei Kwakwa, The long-run effects of energy use, urbanization and financial development on carbon dioxide emissions, 2020, 14, 1750-6220, 1405, 10.1108/IJESM-01-2020-0013 | |
16. | Siming Liu, Qing Wei, Pierre Failler, Hong Lan, Fine Particulate Air Pollution, Public Service, and Under-Five Mortality: A Cross-Country Empirical Study, 2020, 8, 2227-9032, 271, 10.3390/healthcare8030271 | |
17. | Tarek Ghazouani, Impact of FDI inflow, crude oil prices, and economic growth on CO2 emission in Tunisia: Symmetric and asymmetric analysis through ARDL and NARDL approach, 2021, 12, 19986041, 1, 10.21511/ee.12(1).2021.01 | |
18. | Tinghui Li, Junhao Zhong, Mark Xu, Does the Credit Cycle Have an Impact on Happiness?, 2019, 17, 1660-4601, 183, 10.3390/ijerph17010183 | |
19. | Zejun Li, Zimei Huang, Tinghui Li, Jie Yan, Does Economic Growth Driving Force Convert? Evidence from China, 2020, 2020, 1563-5147, 1, 10.1155/2020/2768025 | |
20. | Junhao Zhong, Tinghui Li, Impact of Financial Development and Its Spatial Spillover Effect on Green Total Factor Productivity: Evidence from 30 Provinces in China, 2020, 2020, 1024-123X, 1, 10.1155/2020/5741387 | |
21. | Peng Hou, Yilin Li, Yong Tan, Yuanjie Hou, Energy Price and Energy Efficiency in China: A Linear and Nonlinear Empirical Investigation, 2020, 13, 1996-1073, 4068, 10.3390/en13164068 | |
22. | Wenming Cao, Shuanglian Chen, Zimei Huang, Does Foreign Direct Investment Impact Energy Intensity? Evidence from Developing Countries, 2020, 2020, 1024-123X, 1, 10.1155/2020/5695684 | |
23. | Ismail Bulent Gurbuz, Elcin Nesirov, Gulay Ozkan, Does agricultural value-added induce environmental degradation? Evidence from Azerbaijan, 2021, 0944-1344, 10.1007/s11356-020-12228-3 | |
24. | Tinghui Li, Xue Li, Does structural deceleration happen in China? Evidence from the effect of industrial structure on economic growth quality, 2020, 2, 2689-3010, 155, 10.3934/NAR.2020009 | |
25. | Peirong Chen, Ruhe Xie, Mingxuan Lu, “Resource Conservation” or “Environmental Friendliness”: How do Urban Clusters Affect Total-Factor Ecological Performance in China?, 2020, 17, 1660-4601, 4361, 10.3390/ijerph17124361 | |
26. | Ahdi Noomen Ajmi, Roula Inglesi-Lotz, Revisiting the Kuznets curve hypothesis for Tunisia: carbon dioxide vs. Ecological footprint, 2020, 1556-7249, 1, 10.1080/15567249.2020.1850923 | |
27. | Yvette Baninla, Qian Zhang, Xiaoqi Zheng, Yonglong Lu, Drivers of changes in natural resources consumption of Central African countries, 2022, 2, 2770-4580, 80, 10.3934/ctr.2022005 | |
28. | Xiaoxue Liu, Fuzhen Cao, Shuangshuang Fan, Does Human Capital Matter for China’s Green Growth?—Examination Based on Econometric Model and Machine Learning Methods, 2022, 19, 1660-4601, 11347, 10.3390/ijerph191811347 | |
29. | Gideon Ntim-Amo, Yin Qi, Ernest Ankrah-Kwarko, Martinson Ankrah Twumasi, Stephen Ansah, Linda Boateng Kissiwa, Ran Ruiping, Investigating the validity of the agricultural-induced environmental Kuznets curve (EKC) hypothesis for Ghana: evidence from an autoregressive distributed lag (ARDL) approach with a structural break, 2022, 33, 1477-7835, 494, 10.1108/MEQ-05-2021-0109 | |
30. | Sami Ullah, Muhammad Nadeem, Kishwar Ali, Qaiser Abbas, Fossil fuel, industrial growth and inward FDI impact on CO2 emissions in Vietnam: testing the EKC hypothesis, 2022, 33, 1477-7835, 222, 10.1108/MEQ-03-2021-0051 | |
31. | Paul Adjei Kwakwa, Kwame Adjei-Mantey, Frank Adusah-Poku, The effect of transport services and ICTs on carbon dioxide emissions in South Africa, 2022, 30, 1614-7499, 10457, 10.1007/s11356-022-22863-7 | |
32. | Paul Adjei Kwakwa, Vera Acheampong, Solomon Aboagye, Does agricultural development affect environmental quality? The case of carbon dioxide emission in Ghana, 2022, 33, 1477-7835, 527, 10.1108/MEQ-09-2021-0222 | |
33. | Hamdiyah Alhassan, Paul Adjei Kwakwa, The effect of natural resources extraction and public debt on environmental sustainability, 2022, 1477-7835, 10.1108/MEQ-07-2022-0192 | |
34. | Lili Zhao, Wenhua Liu, Min Zhou, Fenghua Wen, Extreme event shocks and dynamic volatility interactions: The stock, commodity, and carbon markets in China, 2022, 47, 15446123, 102645, 10.1016/j.frl.2021.102645 | |
35. | Gozal Ahmadova, Blanca L. Delgado-Márquez, Javier Aguilera-Caracuel, Reporting of environmental policies and internationalization of Asia–Pacific firms: the moderating role of innovation as a source of legitimacy, 2022, 1472-4782, 10.1057/s41291-022-00203-4 | |
36. | Leonarda Sofiani Rame, Arief Hartono, Irman Firmansyah, The Effect of Demographic Factors on Waste Generation and Heavy Metal in Illegal Landfill at Malaka Regency, East Nusa Tenggara Province, 2022, 950, 1755-1307, 012055, 10.1088/1755-1315/950/1/012055 | |
37. | Vincent Ekow Arkorful, Zhao Shuliang, Benjamin Kweku Lugu, Investigating household waste separation behavior: the salience of an integrated norm activation model and the theory of planned behavior, 2022, 0964-0568, 1, 10.1080/09640568.2022.2063112 | |
38. | Hamdiyah Alhassan, Paul Adjei Kwakwa, Samuel Arkoh Donkoh, The interrelationships among financial development, economic growth and environmental sustainability: evidence from Ghana, 2022, 29, 0944-1344, 37057, 10.1007/s11356-021-17963-9 | |
39. | YuBiao Hao, XueCheng Zhang, The impact of environmental regulation on urban green output efficiency: evidence from China, 2023, 1387-585X, 10.1007/s10668-023-03110-6 | |
40. | Jing Xu, Jinzhi Weng, Rong Yuan, Impacts of financial development on the energy consumption in China from the perspective of poverty alleviation efficiency, 2023, 1614-7499, 10.1007/s11356-023-26759-y | |
41. | Paul Adjei Kwakwa, Solomon Aboagye, Addressing Africa’s carbon dioxide emission: the role of natural resources, control of corruption, voice and accountability and regulatory quality, 2024, 35, 1477-7835, 1437, 10.1108/MEQ-11-2023-0381 | |
42. | Xiao Wang, Jiaojiao Li, Jingming Shi, Jia Li, Jianxu Liu, Songsak Sriboonchitta, Does China–Europe Railway Express Improve Green Total Factor Productivity in China?, 2023, 15, 2071-1050, 8031, 10.3390/su15108031 | |
43. | George E. Halkos, George J. Papageorgiou, Emmanuel G. Halkos, John G. Papageorgiou, Dynamic Modeling of Environmental Subsidies, 2024, 12, 2227-7099, 75, 10.3390/economies12040075 | |
44. | Dilek ÇİL, Ekonomi ve Çevre Etkileşimi: Türkiye'de Finansal Gelişim ve Ulaşım Kaynaklı CO2 İlişkisi Üzerine Fourier ADL Analizi, 2023, 4, 2718-1081, 456, 10.54733/smar.1402556 | |
45. | Inès Gharbi, Md. Hasanur Rahman, Muryani Muryani, Miguel Angel Esquivias, Mohammad Ridwan, Exploring the influence of financial development, renewable energy, and tourism on environmental sustainability in Tunisia, 2025, 6, 2662-9984, 10.1007/s43621-025-00896-5 |
DEGs | Gene title | Gene symbol | LogFC | Biological function |
Down-regulated | Chloride channel accessory 4 | CLCA4 | 4.91 | Calcium sensitive chloride conductance protein |
Zymogen granule protein 16 | ZG16 | 4.45 | Promoting cell growth and stemness. | |
Solute carrier family 4 member 4 | SLC4A4 | 4.43 | Sodium bicarbonate cotransporter | |
Alcohol dehydrogenase 1B (class I), beta polypeptide | ADH1B | 4.29 | Metabolizing ethanol, retinol, and aliphatic alcohol | |
Glucagon | GCG | 4.15 | Counteracting the action of insulin in the bloodstream. | |
Up-regulated | Dipeptidase 1 | DPEP1 | −4.14 | Kidney membrane enzyme |
Keratin 23 | KRT23 | −4.28 | Intermediate filament proteins | |
Claudin 1 | CLDN1 | −4.46 | Tight junctions | |
Leucine rich repeat containing G protein-coupled receptor 5 | LGR5 | −4.51 | Leucine-rich repeat-containing receptor | |
Forkhead box Q1 | FOXQ1 | −5.55 | Embryonic development and cell cycle regulation |
Expression | Category | Term | Count | % | P-Value | FDR |
Down-regulated | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 13 | 0.038728513 | 0.013503078 | 19.70156803 |
GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.035749397 | 0.011658571 | 17.24378143 | |
GOTERM_BP_DIRECT | GO:0008284~positive regulation of cell proliferation | 11 | 0.03277028 | 0.07067658 | 69.36458376 | |
GOTERM_BP_DIRECT | GO:0042493~response to drug | 10 | 0.029791164 | 0.014890967 | 21.50558949 | |
GOTERM_BP_DIRECT | GO:0007399~nervous system development | 9 | 0.026812048 | 0.028891454 | 37.69742039 | |
GOTERM_CC_DIRECT | GO:0016021~integral component of membrane | 83 | 0.247266661 | 0.004198766 | 5.157367461 | |
GOTERM_CC_DIRECT | GO:0005886~plasma membrane | 71 | 0.211517264 | 0.001689338 | 2.105290204 | |
GOTERM_CC_DIRECT | GO:0070062~extracellular exosome | 67 | 0.199600798 | 6.59E-08 | 8.30E-05 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 43 | 0.128102005 | 1.82E-08 | 2.29E-05 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 34 | 0.101289957 | 0.002466544 | 3.060090837 | |
GOTERM_MF_DIRECT | GO:0004089~carbonate dehydratase activity | 5 | 0.014895582 | 1.89E-05 | 0.0259938 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 9 | 0.026812048 | 7.38E-04 | 1.012297275 | |
GOTERM_MF_DIRECT | GO:0005200~structural constituent of cytoskeleton | 7 | 0.020853815 | 0.002187539 | 2.974720065 | |
GOTERM_MF_DIRECT | GO:0005179~hormone activity | 6 | 0.017874698 | 0.005649705 | 7.515474579 | |
GOTERM_MF_DIRECT | GO:0008270~zinc ion binding | 25 | 0.07447791 | 0.007595654 | 9.980321245 | |
Up-regulated | GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.072115385 | 4.45E-05 | 0.070505424 |
GOTERM_BP_DIRECT | GO:0045944~positive regulation of transcription from RNA polymerase Ⅱ promoter | 12 | 0.072115385 | 0.047923342 | 54.04862787 | |
GOTERM_BP_DIRECT | GO:0006508~proteolysis | 10 | 0.060096154 | 0.004653246 | 7.118885476 | |
GOTERM_BP_DIRECT | GO:0045893~positive regulation of transcription, DNA-templated | 10 | 0.060096154 | 0.005625306 | 8.544770506 | |
GOTERM_BP_DIRECT | GO:0000122~negative regulation of transcription from RNA polymerase Ⅱ promoter | 10 | 0.060096154 | 0.040288919 | 47.85424336 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 25 | 0.150240385 | 2.24E-05 | 0.026796109 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 23 | 0.138221154 | 1.30E-05 | 0.015593466 | |
GOTERM_CC_DIRECT | GO:0005887~integral component of plasma membrane | 17 | 0.102163462 | 0.0098955 | 11.22182273 | |
GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 10 | 0.060096154 | 3.33E-05 | 0.039831238 | |
GOTERM_CC_DIRECT | GO:0009986~cell surface | 8 | 0.048076923 | 0.044084961 | 41.70407607 | |
GOTERM_MF_DIRECT | GO:0008009~chemokine activity | 6 | 0.036057692 | 1.24E-05 | 0.016078978 | |
GOTERM_MF_DIRECT | GO:0045236~CXCR chemokine receptor binding | 4 | 0.024038462 | 1.86E-05 | 0.024112254 | |
GOTERM_MF_DIRECT | GO:0004252~serine-type endopeptidase activity | 8 | 0.048076923 | 0.00101144 | 1.305200327 | |
GOTERM_MF_DIRECT | GO:0050840~extracellular matrix binding | 3 | 0.018028846 | 0.01109514 | 13.48485303 | |
GOTERM_MF_DIRECT | GO:0017147~Wnt-protein binding | 3 | 0.018028846 | 0.01556121 | 18.42243874 | |
GO: Gene Ontology; FDR: False Discovery Rate. |
Category | Term | Count | % | P-Value | Genes | FDR |
Down-regulatedDEGs | hsa04978:Mineral absorption | 6 | 0.017874698 | 4.69E-04 | TRPM6, MT1M, MT1E, MT1H, MT1X, MT1F | 0.546769342 |
hsa04972:Pancreatic secretion | 6 | 0.017874698 | 0.010495925 | KCNMA1, CLCA1, CLCA4, ATP2A3, CA2, SLC4A4 | 11.59221263 | |
hsa00910:Nitrogen metabolism | 5 | 0.014895582 | 8.18E-05 | CA12, CA7, CA4, CA2, CA1 | 0.095443878 | |
hsa04960:Aldosterone-regulated sodium reabsorption | 5 | 0.014895582 | 0.002219912 | SGK1, NR3C2, HSD11B2, SCNN1G, SCNN1B | 2.561720438 | |
hsa04976:Bile secretion | 5 | 0.014895582 | 0.016846119 | AQP8, SLC51B, CA2, SLC4A4, ABCG2 | 17.99502607 | |
Up-regulatedDEGs | hsa04062:Chemokine signaling pathway | 7 | 0.042067308 | 0.001681492 | CXCL1, PLCB4, PPBP, CXCL5, CXCL3, CXCL8, CXCL11 | 1.951113014 |
hsa05200:Pathways in cancer | 7 | 0.042067308 | 0.053070195 | BMP4, PLCB4, MET, CXCL8, AXIN2, MYC, MMP1 | 47.1893587 | |
hsa05202:Transcriptional misregulation in cancer | 6 | 0.036057692 | 0.005889645 | MET, CXCL8, MMP3, MYC, WT1, PLAU | 6.682415976 | |
hsa03320:PPAR signaling pathway | 4 | 0.024038462 | 0.011041824 | SCD, ACSL6, MMP1, FABP6 | 12.19046418 | |
hsa05323:Rheumatoid arthritis | 4 | 0.024038462 | 0.022861328 | CXCL5, CXCL8, MMP3, MMP1 | 23.72114711 | |
KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: False Discovery Rat |
Gene | Degree of connectivity | Adjusted P value |
MYC | 34 | 9.25E-11 |
CXCR1 | 28 | 1.87E-03 |
TOP2A | 23 | 2.90E-02 |
CXCL12 | 20 | 1.95E-08 |
SST | 18 | 7.36E-09 |
TIMP1 | 17 | 1.05E-02 |
SPP1 | 17 | 3.95E-02 |
PPBP | 17 | 9.73E-04 |
CDK1 | 16 | 1.13E-02 |
THBS1 | 16 | 2.99E-08 |
CXCL1 | 15 | 1.91E-03 |
PYY | 15 | 1.77E-08 |
LPAR1 | 15 | 8.36E-11 |
BMP2 | 15 | 1.06E-05 |
MMP3 | 14 | 7.22E-05 |
DEGs | Gene title | Gene symbol | LogFC | Biological function |
Down-regulated | Chloride channel accessory 4 | CLCA4 | 4.91 | Calcium sensitive chloride conductance protein |
Zymogen granule protein 16 | ZG16 | 4.45 | Promoting cell growth and stemness. | |
Solute carrier family 4 member 4 | SLC4A4 | 4.43 | Sodium bicarbonate cotransporter | |
Alcohol dehydrogenase 1B (class I), beta polypeptide | ADH1B | 4.29 | Metabolizing ethanol, retinol, and aliphatic alcohol | |
Glucagon | GCG | 4.15 | Counteracting the action of insulin in the bloodstream. | |
Up-regulated | Dipeptidase 1 | DPEP1 | −4.14 | Kidney membrane enzyme |
Keratin 23 | KRT23 | −4.28 | Intermediate filament proteins | |
Claudin 1 | CLDN1 | −4.46 | Tight junctions | |
Leucine rich repeat containing G protein-coupled receptor 5 | LGR5 | −4.51 | Leucine-rich repeat-containing receptor | |
Forkhead box Q1 | FOXQ1 | −5.55 | Embryonic development and cell cycle regulation |
Expression | Category | Term | Count | % | P-Value | FDR |
Down-regulated | GOTERM_BP_DIRECT | GO:0007155~cell adhesion | 13 | 0.038728513 | 0.013503078 | 19.70156803 |
GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.035749397 | 0.011658571 | 17.24378143 | |
GOTERM_BP_DIRECT | GO:0008284~positive regulation of cell proliferation | 11 | 0.03277028 | 0.07067658 | 69.36458376 | |
GOTERM_BP_DIRECT | GO:0042493~response to drug | 10 | 0.029791164 | 0.014890967 | 21.50558949 | |
GOTERM_BP_DIRECT | GO:0007399~nervous system development | 9 | 0.026812048 | 0.028891454 | 37.69742039 | |
GOTERM_CC_DIRECT | GO:0016021~integral component of membrane | 83 | 0.247266661 | 0.004198766 | 5.157367461 | |
GOTERM_CC_DIRECT | GO:0005886~plasma membrane | 71 | 0.211517264 | 0.001689338 | 2.105290204 | |
GOTERM_CC_DIRECT | GO:0070062~extracellular exosome | 67 | 0.199600798 | 6.59E-08 | 8.30E-05 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 43 | 0.128102005 | 1.82E-08 | 2.29E-05 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 34 | 0.101289957 | 0.002466544 | 3.060090837 | |
GOTERM_MF_DIRECT | GO:0004089~carbonate dehydratase activity | 5 | 0.014895582 | 1.89E-05 | 0.0259938 | |
GOTERM_MF_DIRECT | GO:0008201~heparin binding | 9 | 0.026812048 | 7.38E-04 | 1.012297275 | |
GOTERM_MF_DIRECT | GO:0005200~structural constituent of cytoskeleton | 7 | 0.020853815 | 0.002187539 | 2.974720065 | |
GOTERM_MF_DIRECT | GO:0005179~hormone activity | 6 | 0.017874698 | 0.005649705 | 7.515474579 | |
GOTERM_MF_DIRECT | GO:0008270~zinc ion binding | 25 | 0.07447791 | 0.007595654 | 9.980321245 | |
Up-regulated | GOTERM_BP_DIRECT | GO:0008285~negative regulation of cell proliferation | 12 | 0.072115385 | 4.45E-05 | 0.070505424 |
GOTERM_BP_DIRECT | GO:0045944~positive regulation of transcription from RNA polymerase Ⅱ promoter | 12 | 0.072115385 | 0.047923342 | 54.04862787 | |
GOTERM_BP_DIRECT | GO:0006508~proteolysis | 10 | 0.060096154 | 0.004653246 | 7.118885476 | |
GOTERM_BP_DIRECT | GO:0045893~positive regulation of transcription, DNA-templated | 10 | 0.060096154 | 0.005625306 | 8.544770506 | |
GOTERM_BP_DIRECT | GO:0000122~negative regulation of transcription from RNA polymerase Ⅱ promoter | 10 | 0.060096154 | 0.040288919 | 47.85424336 | |
GOTERM_CC_DIRECT | GO:0005576~extracellular region | 25 | 0.150240385 | 2.24E-05 | 0.026796109 | |
GOTERM_CC_DIRECT | GO:0005615~extracellular space | 23 | 0.138221154 | 1.30E-05 | 0.015593466 | |
GOTERM_CC_DIRECT | GO:0005887~integral component of plasma membrane | 17 | 0.102163462 | 0.0098955 | 11.22182273 | |
GOTERM_CC_DIRECT | GO:0005578~proteinaceous extracellular matrix | 10 | 0.060096154 | 3.33E-05 | 0.039831238 | |
GOTERM_CC_DIRECT | GO:0009986~cell surface | 8 | 0.048076923 | 0.044084961 | 41.70407607 | |
GOTERM_MF_DIRECT | GO:0008009~chemokine activity | 6 | 0.036057692 | 1.24E-05 | 0.016078978 | |
GOTERM_MF_DIRECT | GO:0045236~CXCR chemokine receptor binding | 4 | 0.024038462 | 1.86E-05 | 0.024112254 | |
GOTERM_MF_DIRECT | GO:0004252~serine-type endopeptidase activity | 8 | 0.048076923 | 0.00101144 | 1.305200327 | |
GOTERM_MF_DIRECT | GO:0050840~extracellular matrix binding | 3 | 0.018028846 | 0.01109514 | 13.48485303 | |
GOTERM_MF_DIRECT | GO:0017147~Wnt-protein binding | 3 | 0.018028846 | 0.01556121 | 18.42243874 | |
GO: Gene Ontology; FDR: False Discovery Rate. |
Category | Term | Count | % | P-Value | Genes | FDR |
Down-regulatedDEGs | hsa04978:Mineral absorption | 6 | 0.017874698 | 4.69E-04 | TRPM6, MT1M, MT1E, MT1H, MT1X, MT1F | 0.546769342 |
hsa04972:Pancreatic secretion | 6 | 0.017874698 | 0.010495925 | KCNMA1, CLCA1, CLCA4, ATP2A3, CA2, SLC4A4 | 11.59221263 | |
hsa00910:Nitrogen metabolism | 5 | 0.014895582 | 8.18E-05 | CA12, CA7, CA4, CA2, CA1 | 0.095443878 | |
hsa04960:Aldosterone-regulated sodium reabsorption | 5 | 0.014895582 | 0.002219912 | SGK1, NR3C2, HSD11B2, SCNN1G, SCNN1B | 2.561720438 | |
hsa04976:Bile secretion | 5 | 0.014895582 | 0.016846119 | AQP8, SLC51B, CA2, SLC4A4, ABCG2 | 17.99502607 | |
Up-regulatedDEGs | hsa04062:Chemokine signaling pathway | 7 | 0.042067308 | 0.001681492 | CXCL1, PLCB4, PPBP, CXCL5, CXCL3, CXCL8, CXCL11 | 1.951113014 |
hsa05200:Pathways in cancer | 7 | 0.042067308 | 0.053070195 | BMP4, PLCB4, MET, CXCL8, AXIN2, MYC, MMP1 | 47.1893587 | |
hsa05202:Transcriptional misregulation in cancer | 6 | 0.036057692 | 0.005889645 | MET, CXCL8, MMP3, MYC, WT1, PLAU | 6.682415976 | |
hsa03320:PPAR signaling pathway | 4 | 0.024038462 | 0.011041824 | SCD, ACSL6, MMP1, FABP6 | 12.19046418 | |
hsa05323:Rheumatoid arthritis | 4 | 0.024038462 | 0.022861328 | CXCL5, CXCL8, MMP3, MMP1 | 23.72114711 | |
KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: False Discovery Rat |
Gene | Degree of connectivity | Adjusted P value |
MYC | 34 | 9.25E-11 |
CXCR1 | 28 | 1.87E-03 |
TOP2A | 23 | 2.90E-02 |
CXCL12 | 20 | 1.95E-08 |
SST | 18 | 7.36E-09 |
TIMP1 | 17 | 1.05E-02 |
SPP1 | 17 | 3.95E-02 |
PPBP | 17 | 9.73E-04 |
CDK1 | 16 | 1.13E-02 |
THBS1 | 16 | 2.99E-08 |
CXCL1 | 15 | 1.91E-03 |
PYY | 15 | 1.77E-08 |
LPAR1 | 15 | 8.36E-11 |
BMP2 | 15 | 1.06E-05 |
MMP3 | 14 | 7.22E-05 |